Biopharmaceutical company Trevena ( NASDAQ: TRVN ) announced an amendment to its March 2022 ex-US royalty-based financing with R-Bridge Healthcare Fund, L.P. Pursuant to the amendment, the company will receive a $2M payment from R-Bridge and $8M million in future potential tranches.
In addition, the outstanding liability in connection with the royalty financing will be reduced by $10M in connection with the amendment. Trevena ( TRVN ) previously received $30M in non-dilute funding under the royalty financing. More on Trevena Seeking Alpha’s Quant Rating on Trevena Historical earnings data for Trevena Financial information for Trevena.